Skip to content

A clinical trial to study the effect of vitamin D in patients with gum diseases.

A Randomized Controlled Trial for reinforcement of epithelial barrier function by vitamin D induction of the antimicrobial peptide cathelicidine. A novel therapeutic approach in Chronic periodontitis.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009193
Enrollment
40
Registered
2017-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Periodontitis Health Condition 2: M272- Inflammatory conditions of jaws

Interventions

Intervention1: Vitamin D tablets: 2000IU vitamin D tablets daily for 3 months Control Intervention1: Subjects who have not been prescribed Vitamin D: Subjects undergoing only scaling and root planing

Sponsors

Rajiv Gandhi University of Health Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria : 1.Study subjects should be >25 years of age. 2.Patients suffering from chronic periodontitis i.e. a)Bleeding on probing b)Probing pocket depth of >= 5 mm c)Clinical attachment loss of >= 3 mm 3.Patients should be vitamin D sufficient (serum levels 30ng/ml and above) according to vitamin D council. 4.Systemically healthy individuals with minimum 20 teeth in occlusion.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1.Patients with systemic diseases that can impair immune response such as diabetes mellitus, HIV, immunological disorder and hepatitis. 2.Patients on any systemic antibiotics, NSAIDS, steroid therapy and any other drugs which is known to affect the periodontal status. 3.Smokers and former smokers are excluded from the study. 4.Patients who have received periodontal treatment in the preceding year or who have taken antibiotics within the previous 3 months. 5.Pregnant or lactating women and those taking oral contraceptive drugs.

Design outcomes

Primary

MeasureTime frame
Increase in GCF cathelicidine levels.Timepoint: 90 days.

Secondary

MeasureTime frame
Improvement in epithelial barrier functionTimepoint: 90 days

Countries

India

Contacts

Public ContactDr Aditi Bose

Sri Rajiv Gandhi College of Dental Sciences and Hospital

dr.aditi2010@gmail.com8105851209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026